Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons

Opioid Use Disorder Clinical Trial

— GM0020  

Official title:

A Phase II Multi-Center Safety Study Examining the Use of the O'Neil Long Acting Naltrexone Implant (OLANI) in Opioid Dependent Persons Receiving Repeat Dosing

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05382091
• Other study ID #: GM0020
• Secondary ID: 4UH3DA047720-032
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 15, 2024
• Est. completion date: October 15, 2027

Study information

• Verified date: May 2024
• Source: Go Medical Industries Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will examine the safety and efficacy of the O'Neil Long Acting Naltrexone Implant (OLANI) in persons with opioid dependency who are seeking relapse-prevention treatment. All participants will be treated in an open label manner. No randomization will occur. The OLANI is a long-acting biodegradable form of naltrexone which is implanted in the abdominal region. It is hypothesized that the OLANI will produce blood levels sufficient to block the effects of opioids for an extended period allowing patients to engage in psychosocial treatment and recovery over the long term. After the initial set of implants, participants will be offered a second set of implants after 13-24 weeks.

Description:

This is a Phase II, multi-center, open-label study designed to evaluate the safety profile and the efficacy of the OLANI when used in participants who meet the diagnosis of opioid use disorder (OUD), as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and who will be voluntarily seeking relapse-prevention treatment using the naltrexone (NTX) implant.

Participants eligible for the study have diagnosed OUD, have completed withdrawal from opioids, and are no longer physically dependent at the time of study enrollment. After completing the informed consent process for the study, all participants will receive their initial OLANI set (two implants) implanted subcutaneously by a study surgeon and will be followed by a medical and surgical research team, receiving medical management intervention and blood draws to measure levels of NTX and its metabolite, 6-beta-naltrexol (6BN). For interested participants, a second implant set will be offered, with placement 13-24 weeks after the initial procedure, after which all participants will be followed for an additional 24 weeks.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 250
• Est. completion date: October 15, 2027
• Est. primary completion date: October 15, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Men or women between 18 and 65 (inclusive) years old

• Meet criteria for a current (within the previous 12-months) DSM-5 diagnosis of OUD at screening, and voluntarily seeking relapse-prevention treatment with NTX implant

• Completed opioid withdrawal as demonstrated by a negative naloxone challenge test (i.e., has tolerated naloxone 0.8 mg)

• Individuals currently treated with NTX will be eligible to receive the implant at the end of the dosing interval of either Vivitrol or oral NTX

• Have no medical or psychiatric contraindications to treatment either with NTX or with the OLANI, as determined by the site clinician and based on medical history and current health status

• Able to sufficiently speak and understand English and understand study procedures

• Able and willing to provide written informed consent

• Able and willing to provide detailed contact information for both self and for close contact(s) on the locator form

• Able and willing to comply with the requirements and procedures of the protocol, including tolerating a minor surgical procedure with local anesthetic for placement of the implant sets into the subcutaneous tissue of the abdomen

• Have an initial weight between 45.3 and 130 kg (inclusive) or have a BMI of 18.5 to 35.0 (inclusive)

• For female participants of childbearing potential, a willingness to practice an effective method of birth control for the duration of participation in the study. Acceptable methods of birth control are specified on the data collection form and in the Manual of Procedures (MOP), and methods other than those specified are not permitted, except in combination with a study-acceptable method; and willingness to complete urine pregnancy testing to confirm non-pregnant status, as per the study schedule and as requested by the site clinician.

Exclusion Criteria:

• Has a condition, disease state, previous medical history, or observed abnormality(ies) (including physical examination, electrocardiogram [ECG], laboratory evaluation, or urinalysis finding) identified during screening that, in the opinion of the site clinician, would preclude safe participation in the study, would affect the ability of the participant to adhere to the protocol, or would interfere with the study assessments, including, but not limited to the following:

• A significant neurological (including cognitive and psychiatric disorders), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable using protocol-allowed medication(s) for the 30 days immediately preceding the proposed administration of OLANI

• Has had significant suicidal ideation or behavior within the past year

• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value more than three times the upper limit of normal, or a different indicator of clinically significant liver cirrhosis (e.g., bilirubin and albumin will also be assessed)

• Has a condition (e.g., chronic pain) that requires ongoing treatment with opiate based medication

• Has any contraindicated medical condition per the approved labelling for NTX containing products

• Has physiological dependence on alcohol and/or sedative-hypnotics that require medical detoxification

• If female, is currently pregnant or breastfeeding, is planning to conceive during the period of study engagement, has a positive blood pregnancy test, or is unwilling to practice effective contraception during study participation

• Has a known hypersensitivity to NTX

• Is not able to provide blood samples due to extensive vein damage

• Has a known hypersensitivity to polylactic acid based materials, including disposable sutures or implants

• Has a known hypersensitivity to local anesthesia

• Is prone to skin rashes, skin irritation, or has a diagnosed or observed skin condition (e.g., recurrent eczema)

• Is tattooed in the proposed implantation area or demonstrates any abnormal skin tissue in the proposed implantation area

• Currently confined or detained in a penal institution or sentenced to such an institution under a criminal or civil statute or detained in other facilities by virtue of statutes.

• Any additional condition(s) that, in the investigator's opinion, would prohibit the participant from completing the study or that would not be in the best interest of the participant.

Related Conditions & MeSH terms

• Opioid Use Disorder
• Opioid-Related Disorders

Intervention

Drug:
• naltrexone implant
3.6 g per implant set each containing 60% naltrexone

Locations

Country	Name	City	State
n/a

Sponsors (6)

Lead Sponsor	Collaborator
Go Medical Industries Pty Ltd	Columbia University, National Institute on Drug Abuse (NIDA), New York State Psychiatric Institute, The Emmes Company, LLC, University at Buffalo

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment Emergent Adverse Events (TEAEs)	Incidence and Severity of TEAEs	time from from placement of first implant set until immediately before placement of the second implant set (or 24 weeks after first implant set)
Primary	Treatment Emergent Adverse Events (TEAEs)	Incidence and Severity of TEAEs	24 weeks after second implant set
Primary	Treatment Emergent Adverse Events (TEAEs)	Incidence and Severity of TEAEs	through Week 48
Primary	Adverse Events of Special Interest (AESI)	Incidence of AESIs related to the surgical procedure and local reaction to the implant over time	time from from placement of first implant set until immediately before placement of the second implant set (or 24 weeks after first implant set)
Primary	Adverse Events of Special Interest (AESI)	Incidence of AESIs related to the surgical procedure and local reaction to the implant over time	24 weeks after second implant set
Primary	Adverse Events of Special Interest (AESI)	Incidence of AESIs related to the surgical procedure and local reaction to the implant over time	through Week 48
Primary	Deaths	Incidence of study deaths	through Week 48
Primary	Serious Adverse Events (SAEs)	Incidence of SAEs	time from from placement of first implant set until immediately before placement of the second implant set (or 24 weeks after first implant set)
Primary	Serious Adverse Events (SAEs)	Incidence of SAEs	24 weeks after second implant set
Primary	Serious Adverse Events (SAEs)	Incidence of SAEs	through Week 48
Primary	Adverse events (AEs) causing study discontinuation	AEs that lead to study discontinuation	through Week 48
Primary	Opioid overdose events	Incidence of opioid overdose events	time from placement of first implant set until immediately before placement of the second implant set (or 24 weeks after first implant set)
Primary	Opioid overdose events	Incidence of opioid overdose events	24 weeks after second implant set
Primary	Opioid overdose events	Incidence of opioid overdose events	through Week 48
Primary	Laboratory abnormalities	Incidence and Severity of lab abnormalities	through Week 48
Primary	Suicidality	incidence of suicidal ideation and suicidal behavior captured with the Columbia-Suicide Severity Rating Scale (C-SSRS)	through Week 48
Primary	Concomitant medications	Proportion of participants who initiate concomitant medications	through Week 48
Secondary	AUC0-t of naltrexone	area under the plasma concentration-time curve from 0 to the time of last measurable concentration (AUC0-t)	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	AUC0-t of 6-beta-naltrexol	area under the plasma concentration-time curve from 0 to the time of last measurable concentration (AUC0-t)	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	AUC0-infinity of naltrexone	area under the plasma concentration-time curve extrapolated to infinity (AUC0-infinity)	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	AUC0-infinity of 6-beta-naltrexol	area under the plasma concentration-time curve extrapolated to infinity (AUC0-infinity)	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	Cmax of naltrexone	Single-dose pharmacokinetic (PK) measurement of the plasma naltrexone concentration (Cmax) after dosing on Day 1	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	Cmax of 6-beta-naltrexol	Single-dose PK measurement of the plasma 6-beta-naltrexol concentration (Cmax) after dosing on Day 1	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	Tmax of naltrexone	Single-dose PK measurement of the time to reach the maximum plasma naltrexone concentration (Tmax) after dosing on Day 1	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	Tmax of 6-beta-naltrexol	Single-dose PK measurement of the time to reach the maximum plasma naltrexone concentration (Tmax) after dosing on Day 1	collected before each implant administration (pre-dose), and 3 hours, 7 days, 14 days, 28 days, then every 14 days after implant administration until second implant procedure or Week 24
Secondary	Proportion of participants that maintain a minimum plasma concentration (13 weeks)	Proportion of participants who maintain NTX blood levels of =2 ng/mL for =13 weeks	up to Week 48
Secondary	Proportion of participants that maintain a minimum plasma concentration (24 weeks)	Proportion of participants who maintain NTX blood levels of =2 ng/mL for =24 weeks	up to Week 48
Secondary	Abstinence from drugs of abuse by UDS	Proportion of participants who maintain abstinence from opioids, benzodiazepines; barbiturates; cocaine; amphetamine; methamphetamine; phencyclidine (PCP); ecstasy (MDMA); and marijuana (THC) as measured through a urine drug screen (UDS)	pre-dose (prior to each implant procedure), Day 7, Day 14, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Abstinence from drugs of abuse by Timeline Followback (TLFB)	Proportion of participants who maintain abstinence from opioids, benzodiazepines; barbiturates; cocaine; amphetamine; methamphetamine; phencyclidine (PCP); ecstasy (MDMA); and marijuana (THC) as measured through a urine drug screen (UDS)	Baseline, Day 7, Day 14, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Abstinence from alcohol	Proportion of participants who maintain abstinence from alcohol as measured using and alcohol breathalyzer	pre-dose (prior to each implant procedure), Day 7, Day 14, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Opioid craving (VAS)	The craving for opioids will be measured using a horizontal visual analog scale (VAS), which ranges from 0 (no craving) to 10 (most intense craving possible).	Baseline, pre-dose prior to implant (Day 0), Day 7, Day 14, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Opioid withdrawal (SOWS)	The SOWS is a 16-item questionnaire designed to measure the severity of opioid withdrawal symptoms. The participant rates the intensity of symptoms using a 5-point scale; with 0 representing "not at all" and 4 representing "extremely".	pre-dose prior to implant (Day 0), Day 7, Day 14, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Opioid withdrawal (COWS)	The COWS is a questionnaire designed to measure 11 common opioid withdrawal signs and symptoms. The summed score provides information about the severity of opioid withdrawal and the level of physical dependence on opioids. Total scores range from 0 to 47, and withdrawal is classified as mild (5-12), moderate (13-24), moderately severe (25-36), or severe (>36)	pre-dose prior to implant (Day 0), Day 7, Day 14, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Hamilton Depression Rating Scale (HDRS)	Assessment of Depression/Mood via the HDRS, is a clinician-administered instrument, useful for following both depression and suicidal ideation, and for following typical symptoms of subacute withdrawal (e.g., low appetite, fatigue, poor sleep). A score of 1 or more to item 3 (suicidality) prompts a clinician assessment for suicide risk before leaving the clinic.	Baseline, Day 7, Day 14, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Brief Symptom Inventory 18 (BSI-18)	Assessment of Depression/Mood via the BSI-18; comprising 18 items (ranging from 0 = not at all to 4 = extremely), assesses psychiatric symptoms in three distinct domains: depression, anxiety, and somatization. The total score ranges from 0 to 72 with higher scores indicating higher symptom severity.	Baseline, Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Quality of Life Score (QoL)	Quality of life as measured through Quality of Life Enjoyment and Satisfaction Questionnaire (short form). is a 16 item self-administered questionnaire that captures life satisfaction over the past week. Each question is rated on a 5 point scale from 1 (Very Poor) to 5 (Very Good). Scores from the individual items are added together and reported as percentage maximum possible score. The Total Score is reported as percentage maximum possible % Max = Raw-minimum score/maximum score-minimum score. (Raw score minus the minimum possible raw score divided by the maximum possible raw score minus the minimum possible raw score). If items are left blank the maximum and minimum scores must be modified to reflect the number of items scored.	Day 28, Day 42, Day 56, then every 28 days until second implant procedure or Week 48
Secondary	Treatment Satisfaction (TSQM-14)	The TSQM-14 is comprised of 14 questions that provide scores on four scales: effectiveness (3 items), side effects (5 items), convenience (3 items) and global satisfaction (3 items). With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100	Before second implant and Week 37 to 48